Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 212

Global Markets Direct's, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016', provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

  • The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects

  • The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 9
Therapeutics Development 10
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 10
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis 11
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies 12
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes 15
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies 20
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes 24
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 25
Aeolus Pharmaceuticals, Inc. 25
Angion Biomedica Corp. 26
Atox Bio Ltd. 27
BCN Biosciences L.L.C. 28
Bolder Biotechnology, Inc. 29
Cellerant Therapeutics, Inc. 30
Cellphire, Inc. 31
Chrysalis BioTherapeutics, Inc. 32
Cleveland BioLabs, Inc. 33
Cumberland Pharmaceuticals, Inc. 34
Diffusion Pharmaceuticals Inc. 35
GNI Group Ltd. 36
Humanetics Corporation 37
INSYS Therapeutics, Inc. 38
Meabco A/S 39
Neumedicines Inc. 40
Nohla Therapeutics Inc. 41
Onconova Therapeutics, Inc. 42
Original BioMedicals Co. Ltd. 43
PharmaIN Corporation 44
Pluristem Therapeutics Inc. 45
RDD Pharma Ltd. 46
Reata Pharmaceuticals, Inc. 47
RedHill Biopharma Ltd. 48
RxBio, Inc. 49
SK Chemicals Co., Ltd. 50
Soligenix, Inc. 51
Stemedica Cell Technologies, Inc. 52
Terapio Corporation 53
Tonix Pharmaceuticals Holding Corp. 54
Vida Therapeutics Inc. 55
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
A-02 - Drug Profile 67
AB-103 - Drug Profile 68
ABC-294640 - Drug Profile 71
AEOL-10150 - Drug Profile 76
AEOL-10171 - Drug Profile 85
amifostine - Drug Profile 86
Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis - Drug Profile 87
AVMOC-001 - Drug Profile 88
BB-3 - Drug Profile 89
BBT-007 - Drug Profile 92
BBT-015 - Drug Profile 93
BBT-018 - Drug Profile 94
BBT-059 - Drug Profile 95
BCN-057 - Drug Profile 96
BIO-300 - Drug Profile 97
BMX-001 - Drug Profile 100
BPC-2 - Drug Profile 101
C-2E2 - Drug Profile 102
C-2E5 - Drug Profile 103
Cell Therapy for Acute Radiation Syndrome - Drug Profile 104
cerium oxide - Drug Profile 105
CLT-009 - Drug Profile 106
Des-Asp Angiotensin 1 - Drug Profile 107
Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile 108
entolimod - Drug Profile 109
EWA-001 - Drug Profile 116
HSJ-0017 - Drug Profile 117
JP4-039 - Drug Profile 118
LGM-2605 - Drug Profile 120
m-2A2 - Drug Profile 121
molgramostim - Drug Profile 122
monosodium luminol - Drug Profile 123
NMIL-121 - Drug Profile 125
omaveloxolone - Drug Profile 128
ondansetron hydrochloride - Drug Profile 131
ondansetron hydrochloride CR - Drug Profile 132
Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis - Drug Profile 137
pirfenidone - Drug Profile 138
PLXR-18 - Drug Profile 140
RDD-2007 - Drug Profile 146
recilisib sodium - Drug Profile 147
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 149
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 150
Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile 151
Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile 152
RES-529 - Drug Profile 153
RP-239X - Drug Profile 157
rusalatide acetate - Drug Profile 158
Rx-100 - Drug Profile 161
SGX-201 - Drug Profile 163
SGX-202 - Drug Profile 164
SKI-2162 - Drug Profile 167
Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile 168
Small Molecules for Radiation and Chemical Toxicity - Drug Profile 169
Small Molecules for Radiation Toxicity - Drug Profile 170
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 171
ST-266 - Drug Profile 172
ST-7 - Drug Profile 174
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 175
SY-303A - Drug Profile 181
SY-513 - Drug Profile 182
SYGN-305 - Drug Profile 183
SYGN-399 - Drug Profile 184
Thrombosomes - Drug Profile 185
TPO-7630 - Drug Profile 186
TPO-7640 - Drug Profile 187
VEDA-1209 - Drug Profile 188
VTI-1000 Series - Drug Profile 189
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 190
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 195
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 196
Featured News & Press Releases 196
Appendix 206
Methodology 206
Coverage 206
Secondary Research 206
Primary Research 206
Expert Panel Validation 206
Contact Us 206
Disclaimer 207

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2016 15
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Comparative Analysis by Unknown Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Development by Companies, H2 2016 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016 30
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp., H2 2016 31
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd., H2 2016 32
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences L.L.C., H2 2016 33
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H2 2016 34
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H2 2016 35
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire, Inc., H2 2016 36
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016 37
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H2 2016 38
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016 39
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 40
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd., H2 2016 41
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H2 2016 42
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by INSYS Therapeutics, Inc., H2 2016 43
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H2 2016 44
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H2 2016 45
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc., H2 2016 46
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H2 2016 47
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co. Ltd., H2 2016 48
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corporation, H2 2016 49
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H2 2016 50
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H2 2016 51
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 52
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd., H2 2016 53
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H2 2016 54
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co., Ltd., H2 2016 55
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H2 2016 56
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 57
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H2 2016 58
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 59
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Vida Therapeutics Inc., H2 2016 60
Assessment by Monotherapy Products, H2 2016 61
Number of Products by Stage and Target, H2 2016 63
Number of Products by Stage and Mechanism of Action, H2 2016 66
Number of Products by Stage and Route of Administration, H2 2016 69
Number of Products by Stage and Molecule Type, H2 2016 71
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2016 195
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..1), H2 2016 196
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..2), H2 2016 197
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..3), H2 2016 198
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..4), H2 2016 199
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H2 2016 200

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2016 15
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Products, H2 2016 23
Assessment by Monotherapy Products, H2 2016 61
Number of Products by Top 10 Targets, H2 2016 62
Number of Products by Stage and Top 10 Targets, H2 2016 62
Number of Products by Top 10 Mechanism of Actions, H2 2016 65
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 65
Number of Products by Top 10 Routes of Administration, H2 2016 68
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 68
Number of Products by Top 10 Molecule Types, H2 2016 70
Number of Products by Stage and Top 10 Molecule Types, H2 2016 70
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Global Sexual Dysfunction Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the sexual dysfunction partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Sexual Dysfunction Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthca......
  • Global Musculoskeletal Partnering 2010-2017: Deal trends, players and financials
    Published: 01-Feb-2017        Price: US 2995 Onwards        Pages: 1000
    "Delivery of this report will take 1-3 days after purchase." Summary Global Musculoskeletal Partnering 2010-2017: Deal trends, players and financials provides comprehensive understanding and unprecedented access to the musculoskeletal partnering deals and agreements entered into by the worlds leading healthcare companies Description Global Musculoskeletal Partnering 2010 to 2017 provides the full collection of Musculosk......
  • Global Sexual Health Partnering 2010-2017: Deal trends, players and financials
    Published: 01-Feb-2017        Price: US 2995 Onwards        Pages: 250
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Sexual Health Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the sexual health partnering deals and agreements entered into by the worlds leading healthcare companies Description Global Sexual Health Partnering 2010 to 2017 provides the full collection of Sexu......
  • Global Musculoskeletal Symptoms Partnering 2010-2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the musculoskeletal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Musculoskeletal Symptoms Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's lead......
  • Global Hypercholesterolemia Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary The Hypercholesterolemia Partnering 2010-2015 report provides understanding and access to the hypercholesterolemia partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements ......
  • Global Cystic Fibrosis Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the cystic fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Cystic Fibrosis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare com......
  • Global Infertility Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the infertility partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Infertility Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.......
  • Global Transplantation Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the transplantation partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Transplantation Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare com......
  • Global Anthrax Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the anthrax partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Anthrax Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs